TY  - JOUR
AU  - Burnstock, G
AU  - Gentile, D
Y2  - 2020/12/10
Y1  - 2018/06/01
SN  - 1573-9538
UR  - http://hdl.handle.net/11343/253593
AB  - Obesity is a growing worldwide health problem, with an alarming increasing prevalence in developed countries, caused by a dysregulation of energy balance. Currently, no wholly successful pharmacological treatments are available for obesity and related adverse consequences. In recent years, hints obtained from several experimental animal models support the notion that purinergic signalling, acting through ATP-gated ion channels (P2X), G protein-coupled receptors (P2Y) and adenosine receptors (P1), is involved in obesity, both at peripheral and central levels. This review has drawn together, for the first time, the evidence for a promising, much needed novel therapeutic purinergic signalling approach for the treatment of obesity with a 'proof of concept' that hopefully could lead to further investigations and clinical trials for the management of obesity.
LA  - English
PB  - SPRINGER
T1  - The involvement of purinergic signalling in obesity
DO  - 10.1007/s11302-018-9605-8
IS  - Purinergic Signalling
VL  - 14
IS  - 2
SP  - 97-108
L1  - /bitstream/handle/11343/253593/PMC5940632.pdf?sequence=1&isAllowed=y
ER  -